Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma

BJU International

Volumn 110, Issue 7, 2012, Pages 956-960

  Jorns, Jacob ^a   Thiel, David D ^a   Lohse, Christine M ^a   Williams, Adrienne ^a   Arnold, Michelle L ^a   Cheville, John C ^a   Leibovich, Bradley C ^a   Parker, Alexander S ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

kidney neoplasms; renal cell carcinoma; survival; tumour volume

Indexed keywords

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL RATE; TUMOR VOLUME; AGED; CONSERVATIVE TREATMENT; KIDNEY TUMOR; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEPHRECTOMY; ORGAN SPARING TREATMENTS; PROPORTIONAL HAZARDS MODELS; TUMOR BURDEN; YOUNG ADULT;

EID: 84871676530     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.10937.x     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, et al,. Cancer statistics, 2010. CA Cancer J Clin 2001; 60: 277-300
2. Chow WH, Devesa SS, Warren JL, et al,. Rising incidence of renal cell cancer in the United States. JAMA 1999; 281: 1628-31
3. Wallen EM, Pruthi RS, Joyce GF, et al,. Urologic diseases in america project. Kidney cancer. J Urol 2007; 177: 2006-18
4. Ljungberg B, Alamdari FI, Rasmuson T, et al,. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 1999; 84: 405-11
5. Levy DA, Slaton JW, Swanson DA, et al,. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998; 159: 1163-7
6. Lam JS, Leppert JT, Figlin RA, et al,. Surveillance following radical or partial nephrectomy for renal cell carcinoma. Curr Urol Rep 2005; 6: 7-18
7. Figlin R, Pierce WC, Kaboo R, et al,. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol 1997; 158: 740-5
8. Shah JB, Margulis V,. In search of a better crystal ball: recent advances in prognostic markers for clear-cell renal cell carcinoma. Expert Rev Anticancer Ther 2010; 10: 837-42
9. Greene FL, Page DL, Fleming ID, et al,. AJCC Cancer Staging Manual, 6th edn. New York: Springer, 2002
10. Ficarra V, Galfano A, Mancini M, et al,. TNM staging system for renal-cell carcinoma: current status and future perspectives. Lancet Oncol 2007; 8: 554-8
11. Zisman A, Pantuck AJ, Dorey F, et al,. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001; 19: 1649-57
12. Kattan MW, Reuter V, Motzer RJ, et al,. A postoperative nomogram for renal cell carcinoma. J Urol 2001; 166: 63-7
13. Sorbellini M, Kattan MW, Snyder ME, et al,. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005; 173: 48-51
14. Frank I, Blute ML, Cheville JC, et al,. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002; 168: 2395-400
15. Ficarra V, Martignoni G, Lohse C, et al,. External validation of the Mayo Clinic stage, size, grade and necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional clear cell renal cell carcinoma. J Urol 2006; 175: 1235-9
16. Molina AM, Motzer RJ,. Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma. Clin Gentiourin Can 2008; 6 (Suppl. 1): S7-13
17. Volpe A, Patard JJ,. Prognostic factors in renal cell carcinoma. World J Urol 2010; 28: 319-27
18. Mancini V, Battaglia M, Ditonno P, et al,. Current insights in renal cell cancer pathology. Urol Oncol 2008; 26: 225-38
19. Frank I, Blute ML, Cheville JC, et al,. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol 2003; 170: 2217-20
20. Fergany AF, Hafez KS, Novick AC,. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. J Urol 2000; 163: 442-5
21. Crispin PL, Boorjian SA, Lohse CL, et al,. Outcomes following partial nephrectomy by tumor size. J Urol 2008; 180: 1912-7
22. Kunkle DA, Egelston BL, Uzzo RG,. Excise, ablate or observe: the small renal mass dilemma-a meta-analysis and review. J Urol 2008; 179: 1227-34
23. Remzi M, Javadli E, Ozsoy M,. Management of small renal masses: a review. World J Urol 2010; 28: 275-81
24. Aron M, Gill IS,. Minimally invasive nephron-sparing surgery (MINSS) for renal tumours. Part II: probe ablative therapy. Eur Urol 2007; 51: 348-57
25. Mahnken AH, Gunther RW, Tacke J,. Radiofrequency ablation of renal tumors. Eur Radiol 2004; 14: 1449-55
26. Lee SE, Lee WK, Kim DS, et al,. Comparison of radiographic and pathologic sizes of renal tumors. World J Urol 2010; 28: 263-7
27. Simmons MN,. Morphometric characterization of kidney tumors. Curr Opin Urol 2011; 21: 99-103